Genelux Future Growth
Future criteria checks 2/6
Genelux is forecast to grow earnings and revenue by 12% and 83.6% per annum respectively while EPS is expected to grow by 20.4% per annum.
Key information
12.0%
Earnings growth rate
20.4%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 83.6% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 19 Nov 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 5 | -54 | -44 | N/A | 4 |
| 12/31/2025 | N/A | -42 | -30 | -22 | 5 |
| 12/31/2024 | 0 | -28 | -5 | -22 | 5 |
| 9/30/2024 | 0 | -28 | -24 | -24 | N/A |
| 6/30/2024 | 0 | -27 | -22 | -21 | N/A |
| 3/31/2024 | 0 | -26 | -21 | -20 | N/A |
| 12/31/2023 | 0 | -28 | -21 | -20 | N/A |
| 9/30/2023 | 0 | -25 | -16 | -15 | N/A |
| 6/30/2023 | 11 | -15 | -15 | -14 | N/A |
| 3/31/2023 | 11 | -12 | -11 | -11 | N/A |
| 12/31/2022 | 11 | -5 | -4 | -4 | N/A |
| 9/30/2022 | 11 | -5 | -1 | -1 | N/A |
| 6/30/2022 | N/A | -13 | -1 | -1 | N/A |
| 3/31/2022 | N/A | -17 | -1 | -1 | N/A |
| 12/31/2021 | N/A | -16 | -7 | -7 | N/A |
| 3/31/2021 | N/A | -13 | -8 | -8 | N/A |
| 12/31/2020 | N/A | -14 | -7 | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GNLX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GNLX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GNLX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GNLX's revenue (83.6% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: GNLX's revenue (83.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GNLX's Return on Equity is forecast to be high in 3 years time